0000950170-24-000450.txt : 20240102 0000950170-24-000450.hdr.sgml : 20240102 20240102200613 ACCESSION NUMBER: 0000950170-24-000450 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240101 FILED AS OF DATE: 20240102 DATE AS OF CHANGE: 20240102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jacques Rachelle Suzanne CENTRAL INDEX KEY: 0001772610 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36288 FILM NUMBER: 24504088 MAIL ADDRESS: STREET 1: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC STREET 2: 100 RIVER RIDGE DRIVE CITY: NORWOOD STATE: MA ZIP: 02062 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akari Therapeutics Plc CENTRAL INDEX KEY: 0001541157 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981034922 STATE OF INCORPORATION: X0 BUSINESS ADDRESS: STREET 1: 22 BOSTON WHARF ROAD STREET 2: FL 7 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (646) 350-0702 MAIL ADDRESS: STREET 1: 22 BOSTON WHARF ROAD STREET 2: FL 7 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Celsus Therapeutics Plc. DATE OF NAME CHANGE: 20130621 FORMER COMPANY: FORMER CONFORMED NAME: Morria Biopharmaceuticals PLC DATE OF NAME CHANGE: 20120201 3 1 ownership.xml 3 X0206 3 2024-01-01 0 0001541157 Akari Therapeutics Plc AKTX 0001772610 Jacques Rachelle Suzanne C/O AKARI THERAPEUTICS, PLC 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 true true false false Chief Executive Officer Ordinary Shares, par value $0.0001 per share 538457900 D Stock Option (Right to Buy) 0.0124 2032-06-01 Ordinary Shares, par value $0.0001 per share 207634400 D Stock Option (Right to Buy) 0.0124 2032-07-29 Ordinary Shares, par value $0.0001 per share 29762300 D Stock Option (Right to Buy) 0.0016 2023-06-01 2033-06-01 Ordinary Shares, par value $0.0001 per share 152690700 D Securities beneficially owned totaling 538,457,900 includes 153,397,775 ordinary shares, par value $0.0001per share ("Ordinary Shares") owned and 385,060,125 of unvested time-based restricted stock units held by the Reporting Person. The stock option award was granted under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). The stock option vests and becomes exercisable ratably on a semiannual basis over a four-year period commencing on March 28, 2022, subject to continued service with the Issuer. The stock option award was granted under the Issuer's 2014 Plan. The stock option vests and becomes exercisable ratably on a semiannual basis over a four-year period commencing on June 1, 2023, subject to continued service with the Issuer. /s/ Rachelle Jacques 2024-01-02